Why the study?
Do direct oral anticoagulants prevent stroke and systemic embolic events as effectively as warfarin without increasing major bleeding in atrial fibrillation patients with chronic kidney disease?
Do direct oral anticoagulants prevent stroke and systemic embolic events as effectively as warfarin without increasing major bleeding in atrial fibrillation patients with chronic kidney disease?
DOACs are as effective as warfarin for stroke prevention without increasing major bleeding risk in atrial fibrillation patients with chronic kidney disease, particularly stage G3.
No takes yet. Share an insight, caveat, or question.
Supports DOAC preference in AF with kidney impairment; confirms comparable efficacy and safety versus warfarin.
Kimachi et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: